{"transactions":[{"id":4629156,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-02T21:19:35.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":4.51,"value":90200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":861076,"source":{"system":"sec-edgar","filing":"0001213900-26-106531","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777328/000121390026106531/ownership.xml","form_type":"4"}},{"id":4626995,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-25T20:30:46.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":209291,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the \"Plan\"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan."}],"balance_after":881076,"source":{"system":"sec-edgar","filing":"0001213900-26-103535","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777328/000121390026103535/ownership.xml","form_type":"4"}},{"id":677454,"issuer":{"id":7620,"kind":"organization","name":"Lifeward Ltd.","symbol":"LFWD"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, no par value per share","published_at":"2026-08-24T21:08:56.000Z","date":"2026-08-20","kind":"grant","planned":false,"acquired":true,"shares":13643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 13,643 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units (\"RSUs\") granted on August 20, 2026 (the \"Grant Date\") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments commencing from the Grant Date."}],"balance_after":13643,"source":{"system":"sec-edgar","filing":"0001178913-26-004241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777328/000117891326004241/ownership.xml","form_type":"4"}},{"id":718769,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T21:00:07.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":73360,"price":4.5085,"value":330743.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.255 to $4.750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":671785,"source":{"system":"sec-edgar","filing":"0001213900-26-075069","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026075069/ownership.xml","form_type":"4"}},{"id":835479,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-18T21:45:50.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":95889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer."}],"balance_after":745145,"source":{"system":"sec-edgar","filing":"0001213900-26-031011","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026031011/ownership.xml","form_type":"4"}},{"id":928068,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2026-01-29T21:05:32.000Z","date":"2026-01-22","kind":"exercise","planned":false,"acquired":false,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001213900-26-009476","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026009476/ownership.xml","form_type":"4"}},{"id":928067,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-29T21:05:32.000Z","date":"2026-01-22","kind":"exercise","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."}],"balance_after":649256,"source":{"system":"sec-edgar","filing":"0001213900-26-009476","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026009476/ownership.xml","form_type":"4"}},{"id":955445,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2026-01-03T01:00:51.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."}],"balance_after":19000,"derivative":{"underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001213900-26-000658","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026000658/ownership.xml","form_type":"4"}},{"id":955444,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-03T01:00:51.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."}],"balance_after":630256,"source":{"system":"sec-edgar","filing":"0001213900-26-000658","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026000658/ownership.xml","form_type":"4"}},{"id":955443,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-03T01:00:51.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":81216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."}],"balance_after":515256,"source":{"system":"sec-edgar","filing":"0001213900-26-000658","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026000658/ownership.xml","form_type":"4"}},{"id":1274387,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-11T21:30:51.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares issued on settlement of PSUs previously granted on January 2, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":434040,"source":{"system":"sec-edgar","filing":"0001213900-25-012238","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012238/ownership.xml","form_type":"4"}},{"id":1274386,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-11T21:30:51.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued on settlement of performance stock units (\"PSUs\") previously granted on June 20, 2024 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":392040,"source":{"system":"sec-edgar","filing":"0001213900-25-012238","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012238/ownership.xml","form_type":"4"}},{"id":1311340,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-06T21:10:10.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":188000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in quarterly installments of approximately 15,666 over a three year period starting January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":358040,"source":{"system":"sec-edgar","filing":"0001213900-25-001166","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025001166/ownership.xml","form_type":"4"}},{"id":1371699,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-11-08T21:30:26.000Z","date":"2024-11-07","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of 30,000 Restricted Stock Units (\"RSUs\") that will vest on November 7, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":170040,"source":{"system":"sec-edgar","filing":"0001213900-24-095932","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024095932/ownership.xml","form_type":"4"}},{"id":1472334,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-06-21T20:15:23.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":140040,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of 140,040 Restricted Stock Units (\"RSUs\"), of which 93,360 will vest on June 18, 2026 and the remaining 46,680 will vest in four equal quarterly installments of 11,670 starting September 18, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-24-054781","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024054781/ownership.xml","form_type":"4"}},{"id":2874786,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-08T22:29:14.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Stock Option will vest in 4 equal installments as follows: 10,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in 4 equal installments as follows: 10,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024."}],"balance_after":40000,"derivative":{"exercise_price":10.4,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-21-007494","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390021007494/ownership.xml","form_type":"4"}},{"id":3414027,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2019-09-16T22:06:19.000Z","date":"2019-09-12","kind":"grant","acquired":true,"shares":33146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on June 17, 2019 and provides for vesting in 4 installments as follows: 5,396 shall vest on December 31, 2019; and 9,250 shall vest on each of December 31, 2020, December 31, 2021 and December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on June 17, 2019 and provides for vesting in 4 installments as follows: 5,396 shall vest on December 31, 2019; and 9,250 shall vest on each of December 31, 2020, December 31, 2021 and December 31, 2022."}],"balance_after":33146,"derivative":{"exercise_price":3.55,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":33146},"source":{"system":"sec-edgar","filing":"0001213900-19-018197","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390019018197/ownership.xml","form_type":"4"}},{"id":3414026,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2019-09-16T22:06:19.000Z","date":"2019-06-17","kind":"disposition_to_issuer","acquired":false,"shares":33146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on June 17, 2019 and provides for vesting in 4 installments as follows: 5,396 shall vest on December 31, 2019; and 9,250 shall vest on each of December 31, 2020, December 31, 2021 and December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on June 17, 2019 and provides for vesting in 4 installments as follows: 5,396 shall vest on December 31, 2019; and 9,250 shall vest on each of December 31, 2020, December 31, 2021 and December 31, 2022."}],"balance_after":0,"derivative":{"exercise_price":3.55,"expiration_date":"2029-06-17","underlying":"Common Stock","underlying_shares":33146},"source":{"system":"sec-edgar","filing":"0001213900-19-018197","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390019018197/ownership.xml","form_type":"4"}},{"id":3476967,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":20368,"kind":"person","name":"Gabay Avraham","position":1,"cik":"0001777328","reported_name":"Gabay Avraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2019-06-27T20:20:32.000Z","date":"2019-06-17","kind":"grant","acquired":true,"shares":33146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in 4 installments as follows: 5,396 shall vest on December 31, 2019; and 9,250 shall vest on each of December 31, 2020, December 31, 2021 and December 31, 2022."}],"balance_after":33146,"derivative":{"exercise_price":3.55,"expiration_date":"2029-06-17","underlying":"Common Stock","underlying_shares":33146},"source":{"system":"sec-edgar","filing":"0001213900-19-011646","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390019011646/ownership.xml","form_type":"4"}}]}